Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state-Reference-Cited by-同舟云学术

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

Published:2019-04-17 Issue:488 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Echeverria Gloria V.¹^ORCID,Ge Zhongqi¹²,Seth Sahil³⁴⁵^ORCID,Zhang Xiaomei¹,Jeter-Jones Sabrina¹^ORCID,Zhou Xinhui¹,Cai Shirong¹,Tu Yizheng¹,McCoy Aaron¹,Peoples Michael⁴⁵^ORCID,Sun Yuting⁴⁵,Qiu Huan⁶,Chang Qing⁴⁵,Bristow Christopher⁴⁵,Carugo Alessandro⁴⁵,Shao Jiansu¹,Ma Xiaoyan⁴⁵,Harris Angela⁴⁵^ORCID,Mundi Prabhjot⁷,Lau Rosanna⁸^ORCID,Ramamoorthy Vandhana⁴⁵,Wu Yun⁸,Alvarez Mariano J.⁷⁹^ORCID,Califano Andrea⁷,Moulder Stacy L.¹⁰,Symmans William F.⁸^ORCID,Marszalek Joseph R.⁴⁵^ORCID,Heffernan Timothy P.⁴⁵^ORCID,Chang Jeffrey T.²⁶,Piwnica-Worms Helen¹^ORCID

Affiliation:

1. Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

2. Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

3. Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

4. Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

5. Center for Co-Clinical Trials Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

6. Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, TX 77030, USA.

7. Department of Systems Biology, Columbia University Medical Center, New York, NY 10032, USA.

8. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

9. DarwinHealth Inc., New York, NY 10018, USA.

10. Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer can be mediated by a reversible chemotherapy-tolerant state.

Funder

American Cancer Society

Cancer Prevention and Research Institute of Texas

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference56 articles.

1. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

3. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

4. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

5. Subclonal diversification of primary breast cancer revealed by multiregion sequencing

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer;JCI Insight;2024-09-10

2. Three-dimensional analysis of mitochondria in a patient-derived xenograft model of triple negative breast cancer reveals mitochondrial network remodeling following chemotherapy treatments;2024-09-09

3. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

4. Hypertranscription: the invisible hand in stem cell biology;Trends in Genetics;2024-09

5. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14